Each gram of cream contains 0.064% w/w of betamethasone dipropionate (equivalent to 0.05% w/w betamethasone) with chlorocresol 0.1% as preservative.
Each gram of ointment contains 0.064% w/w of betamethasone dipropionate (equivalent to 0.05% w/w betamethasone).
Betamethasone Dipropionate is a topically active fluorinated corticosteroid which has anti-inflammatory, antipruritic and vasoconstrictive actions.
Pharmacology: Corticosteroids are extensively bound to plasma protein. Only unbound corticosteroids have pharmacological effects or are metabolised. They are metabolised mainly in the liver and also in the kidney, and are excreted in the urine.
For the relief of inflammatory manifestations of corticosteroids-responsive dermatoses.
Apply a thin film to the affected skin areas once or twice daily as directed by the doctor or pharmacist.
Corticosteroid applied to the skin can be absorbed in sufficient amounts to produce systemic effects such as hypothalamic-pituitary-adrenal axis suppression, manifestation of cushing's syndrome, hyperglycaemia and glucosuria. Tests which may be helpful in evaluating hypothalamic-pituitary-adrenal axis suppression include urinary free cortisol test and ACTH stimulation test. If hypothalamic-pituitary-adrenal axis suppression is found, then the drug should be withdrawn, frequency of application reduced or a weaker steroid used. Supplemental systemic corticosteroids may be required if signs and symptoms of steroid withdrawal occur.
Hypersensitivity to betamethasone dipropionate, other corticosteroids, or any component in the base.
Discontinue use if irritation, sensitivity or other reaction develops and institute appropriate treatment. Corticosteroid applied to the skin can be absorbed in sufficient amounts to produce systemic effects such as hypothalamic-pituitary-adrenal axis suppression, manifestation of Cushing's sydrome, hyperglycaemia and glucosuria. Thus suitable precautions should be taken during prolonged treatment, when treating extensive body surface areas, when using the occlusive technique and when treating children (because of a larger skin surface area to bodyweight ratio).
Safety of use of topical corticosteroids during pregnancy and lactation has not been established.
Reported local adverse reactions are burning sensation, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Keep container well closed. Protect from strong light. Store below 30°C. For external use only.
Recommended shelf-life: 3 years.
D07AC01 - betamethasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
Cream (white) 0.064% x 15 g. Oint (white) 0.064% x 15 g.